| NANO-technology |
Study ID |
Study Title |
Phase |
Drug |
Study design |
Study arms |
Condition |
| Immunotherapy |
NCT02054520 |
Immunotherapy Study for Patients With Stage IV Melanoma |
IIB |
HyperAcute®-Melanoma (HAM) Immunotherapy |
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment |
Experimental: HyperAcute®-Melanoma (HAM) Immunotherapy + Ipilimumab
Active Comparator: Ipilimumab Alone
|
Stage 4 melanoma |
| Polymeric Nanoparticles |
NCT02158520 |
Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery |
II |
paclitaxel albumin-stabilized nanoparticle formulation |
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment |
Experimental: Arm A (nab-paclitaxel and bevacizumab)
Experimental: Arm B (ipilimumab)
|
• Stage IIIA Melanoma
• Stage IIIB Melanoma
• Stage IIIC Melanoma
Stage IV Melanoma |
Polymeric
Nanoparticles |
NCT00626405 |
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery |
II |
Biological: bevacizumab
Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Drug: temozolomide |
Allocation: Randomized
Primary Purpose: Treatmen |
Experimental: Arm I
Interventions:
• Biological:bevacizumab
Drug: temozolomide
Experimental: Arm II
Interventions:
• Biological: bevacizumab
• Drug: carboplatin
Drug: paclitaxel albumin-stabilized nanoparticle formulation |
MELANOMA |
| siRNA |
NCT00689065 |
A Phase I, Dose-Escalating Study of the Safety of Intravenous CALAA-01 in Adults With Solid Tumors Refractory to Standard-of-Care Therapies |
I |
CALAA-01: a small interfering RNA (siRNA). This siRNA inhibits tumor growth via RNA interference to reduce expression of the M2 subunit of ribonucleotide reductase (R2). The CALAA-01 siRNA is protected from nuclease degradation within a stabilized nanoparticle targeted to tumor cells. |
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatmen |
Experimental: CALAA-01
Intervention: Drug: CALAA-01 |
Solid Tumours |
| Polymeric Nanoparticles |
NCT00404235 |
Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery |
ii |
• Drug: carboplatin
• Drug: paclitaxel albumin-stabilized nanoparticle formulation
|
Masking: Open Label
Primary Purpose: Treatment |
This phase II trial is studying the side effects and how well giving carboplatin together with ABI-007 works in treating patients with stage IV melanoma that cannot be removed by surgery. |
Melanoma |
| Quantum Dots |
NCT02106598 |
Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Prostate and Cervical/Uterine Cancer Patients |
0 |
fluorescent cRGDY-PEG-Cy5.5-C dots |
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic |
Melanoma patients will be injected with a radioactive dye around the tumor site, and images will be acquired about 2 hours the location of the later using a device to image the dye. |
|
| ADC (antibody drug conjugates) |
NCT02129075 |
CDX-1401 and Poly-ICLC Vaccine Therapy With or Without CDX-301in Treating Patients With Stage IIB-IV Melanoma |
ii |
|
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment |
This randomized phase II trial studies how well DEC-205/NY-ESO-1 fusion protein CDX-1401 (CDX-1401) and neoantigen-based melanoma-poly-ICLC vaccine (poly-ICLC) vaccine therapy work when given with or without recombinant flt3 ligand (CDX-301) in treating patients with stage IIB-IV melanoma |
|
| Immunotherapy |
NCT01814046 |
Adoptive T Cell Therapy for Metastatic Ocular Melanoma |
II |
Drug: Aldesleukin |
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment |
Participants will receive an infusion of their collected white blood cells. They will also receive aldesleukin for up to 5 days to boost the immune system's response to the white blood cells. |
• Metastatic Ocular Melanoma
Metastatic Uveal Melanoma |
| Immunotherapy |
NCT01863108 |
Safety Study of a Dendritic Cell-based Cancer Vaccine in Melanoma |
i |
GeniusVac-Mel4:a drug product composed of an irradiated allogeneic plasmacytoid dendritic cell (PDC) line loaded with 4 melanoma peptides derived from Melan-A, gp100, Tyrosinase or Mage-A3 |
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment |
Experimental: GeniusVac-Mel4
Sub-cutaneous injections of GeniusVac-Mel4 in patients with melanoma.
Intervention: Biological: GeniusVac-Mel4 |
melanoma |
| Quantum Dots |
NCT01266096 |
PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study |
|
PET scan with 124I-cRGDY-PEG-dots |
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic |
|
• Newly Diagnosed or Recurrent Metastatic Melanoma Patients
Malignant Brain Tumors |
| siRNA |
NCT01941927 |
Trametinib With GSK2141795 in BRAF Wild-type Melanoma |
Ii |
• Drug: Trametinib (GSK1120212)
Drug: GSK2141795 |
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment |
|
|
| Tumour targetting |
NCT02236546 |
FDG-PET/CT as a Biomarker for Treatment Response in Advanced Melanoma |
|
18F]fluorodeoxyglucose
(FDG) |
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic |
Patients undergo [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) up to 2 weeks prior to first dose of therapy, after completion of the first treatment course (day 21), and after completion of the fourth treatment course (day 84). |
• Recurrent Melanoma
• Stage IIIA Melanoma
• Stage IIIB Melanoma
• Stage IIIC Melanoma
Stage IV Melanoma |
| Imaging |
NCT02106598 |
Targeted Silica Nanoparticles for Image-Guided Intraoperative Sentinel Lymph Node Mapping in Head and Neck Melanoma, Prostate and Cervical/Uterine Cancer Patients |
0 |
fluorescent cRGDY-PEG-Cy5.5-C dots |
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic |
Melanoma patients will be injected with a radioactive dye around the tumor site, and images will be acquired about 2 hours the location of the later using a device to image the dye. |
• Head and Neck Cancer
• Melanoma
• Prostate Cancer
• Cervical Cancer
Uterine Cancer |
| Imaging |
|
Sentinel Node Biopsy using Magnetic Nanoparticles for melanoma |
|
Sienna+ |
Detection rate with either the standard (blue dye and isotope) or the new technique (magnetic)
Timepoint(s): The proportion of sentinel nodes detected (detection rate) with either the standard or the new magnetic technique |
Non-randomised; Interventional; Design type: Diagnosis |
melanoma |
| siRNA |
NCT00672542 |
Immunotherapy of
Melanoma With Tumor
Antigen RNA and
Small Inhibitory RNA
Transfected Autologous
Dendritic Cells |
I |
Proteasome siRNA
and tumor antigen
RNA-transfected
dendritic cells |
Allocation: Non-
Randomized
Endpoint Classification:
Safety Study
Intervention Model: Single
Group Assignment
Masking: Open Label
Primary Purpose:
Treatment |
• Experimental: A
siRNA loaded
dendritic cells derived
from untreated
monocytes Intervention:
Biological: Proteasome
siRNA and tumor
antigen RNAtransfected
dendritic
cells
• Experimental: B
Vaccination with
melanoma tumor
associated antigen
RNA loaded dendritic
cells derived from
monocytes transfected
with control siRNA
Intervention: Biological:
Proteasome siRNA and
tumor antigen RNAtransfected
dendritic
cells
Experimental: C
Vaccination with
melanoma tumor
associated antigen
RNA loaded dendritic
cells derived from
monocytes transfected
with siRNA targeting
the three inducible
immunoproteasome
subunits Intervention:
Biological: Proteasome
siRNA and tumor
antigen RNAtransfected
dendritic
cells |
Metastatic
Melanoma with
Absence of CNS
Metastases |
| siRNA |
NCT02166255 |
APN401 in Treating
Patients With Melanoma,
Kidney Cancer,
Pancreatic Cancer, or
Other Solid Tumors That
Are Metastatic or Cannot
Be Removed By Surgery |
I |
siRNA-transfected
peripheral blood
mononuclear cells
APN401 |
Endpoint Classification:
Safety/Efficacy Study
Intervention Model: Single
Group Assignment
Masking: Open Label
Primary Purpose:
Treatment |
Experimental:
Treatment (APN401) |
• Recurrent
Melanoma
• Recurrent
Pancreatic Cancer
• Recurrent
Renal Cell Cancer
• Stage III
Pancreatic Cancer
• Stage III Renal
Cell Cancer
• Stage IIIA
Melanoma
• Stage IIIB
Melanoma
• Stage IIIC
Melanoma
• Stage IV
Melanoma
• Stage IV
Pancreatic Cancer
• Stage IV Renal
Cell Cancer
Unspecified Adult
Solid Tumor,
Protocol Specific |
